glp-1 nejm In the ATTAIN-1 phase 3, randomized trial, the use of orforglipron, an oral glucagon-like peptide-1 receptor agonist, led to significant mean body-weight reductions in patients with obesity, as compared with placebo. Full New @NEJM review on GLP-1
Description
Social media is packed with claims of finding natures Ozempic. How legitimate are these claims

Immunology drugs are still profitable

More and more women are reporting that drugs for weight loss are helping with fertility.

METABOLISM SUPPORT: Powered by GreenSelect Phytosome, Clinical research shows this unique green tea extract, when combined with a reduced-calorie diet, can support healthy weight management and a reduced waist size
